<DOC>
	<DOCNO>NCT02275663</DOCNO>
	<brief_summary>The purpose phase 2 study test efficacy azacytidine give prior fludarabine , cytarabine , G-CSF treatment relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Azacytidine Plus FLAG Relapsed Refractory AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age 16 60 2 . Patients diagnosis relapse refractory AML ( ≥ 20 % blast bone marrow ) . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 4 . Patients must preserve organ function define : Creatinine ≤ 1.5 mg/dl Total bilirubin ≤ 1.5x upper limit normal Alanine aminotransferase ( ALT ) ≤ 2x upper limit normal Left ventricular ejection fraction ( LVEF ) ≥ 45 % 1 . Patients diagnosis acute promyelocytic leukemia ( AML M3 ) 2 . Pregnant woman 3 . Patients previously treat fludarabine allow participate . 4 . Patients Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>relapse AML</keyword>
	<keyword>refractory AML</keyword>
	<keyword>azacytidine</keyword>
</DOC>